Skip to main content

Table 4 Incidence of CMV disease and asymptomatic CMV infection in R+ recipients according to era after HTx

From: Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients

Era

Prophylaxis

CMV disease, n (%)

Asymptomatic CMV infection, n (%)

No CMV, n (%)

1988–1991 (n = 59)

No

11 (19)

8 (13)

40 (68)

1992–1997 (n = 74)

Targeteda

11 (15)

17 (23)

46 (62)

1998–2000 (n = 32)

Targeteda

10 (31)

6 (19)

16 (50)

Total (n = 165)

 

32 (19)

31 (19)

102 (62)

  1. aTargeted prophylaxis given with 5 mg/kg of i.v. ganciclovir bid for 10 days in association with the first anti-rejection treatment with ATG and the second anti-rejection treatment with high-dose corticosteroids within the first 4 months post-transplantation
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us